Karin Blakolmer MD MBA has over 20 years of oncology experience in drug development and medical affairs in large and mid-sized pharma (Roche, Novartis, Sanofi, Astellas, Taiho). Member of the executive leadership team with US, European and global roles in life-cycle management across the marketed drug portfolio and R&D pipeline including drug launches and HEOR. Joined Parow Entheobiosciences in 2021, a startup that aims to develop accessible treatments for psychiatric conditions based on entheogenic molecules through a rigorous, science-based approach from discovery to clinical trials and manufacturing.